LBPO.ET01 · 实验与分子治疗 · Late-Breaking

CRAF与RAS结合的正构和别构决定因素

Orthosteric and allosteric determinants of CRAF binding to RAS

海报缩略图:CRAF与RAS结合的正构和别构决定因素
编号 LB066 展板 19 时间 4/19 02:00–05:00 区域 Section 52 主讲 Oliver Priebe, BA
分会场 Late-Breaking Research: Experimental and Molecular Therapeutics 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Oliver Priebe, Chandni Khandwala, Francisco Guedes, Max Seaman, Sabine Ruppel, Adam Yaari, Maxwell Sherman

Serinus Biosciences Inc., New York, NY

摘要 Abstract

中文摘要
细胞内蛋白质-蛋白质相互作用是信号转导和转录重编程等致癌过程的关键驱动因素。虽然蛋白质-蛋白质界面传统上难以用小分子成药,但分子胶正作为一种有前景的治疗手段出现,可将靶蛋白的相互作用从致病性伙伴转移开。然而,由于对蛋白质在原子水平上如何相互作用的生物物理理解有限,分子胶的理性发现仍具有挑战性。为应对这一挑战,我们开发了一种大规模多重化方法,以测量序列变异对真核细胞内蛋白质-蛋白质相互作用亲和力的影响。在此,我们应用该技术,通过对CRAF Ras结合结构域(CRAF RBD)进行深度饱和突变,以单残基分辨率绘制CRAF与HRAS之间的结合能量学图谱。在单个多重化测定中,我们测量了1,501个CRAF变体的结合亲和力,包括CRAF RBD所有可能的单残基替换。自由能估计值与金标准生物物理测量高度一致(Pearson R=0.93,P=6.8×10-4,N=8个突变),并证实我们的技术能够灵敏地检测高亲和力(纳摩尔级KD)和低亲和力(微摩尔级KD)的结合事件。将突变数据与界面的晶体结构相整合,得到了该相互作用结合能量学的三维空间图谱。该图谱鉴定了使相互作用去稳定的正构界面残基和别构非界面残基。它还揭示了一类同时降低CRAF整体稳定性并增强对HRAS结合亲和力的序列变体。由于纯化不稳定蛋白质的难度,这类突变可能难以用传统生物物理技术发现。此外,它们可通过为模拟这些增强相互作用的分子提供路线图,直接为理性分子胶设计提供信息。最后,我们证明了丰富的突变能量学数据可提高AI蛋白质结构预测模型在蛋白质复合物预测任务上的准确性。这一进展使得为缺乏已解析结构的蛋白质界面生成三维能量学图谱成为可能。我们的结果提供了CRAF RBD与HRAS结合的正构和别构决定因素图谱。鉴于RAS抑制剂耐药机制不断涌现的态势,该图谱对RAS和RAF调节剂的开发具有直接应用价值。这项工作还展示了一种高度可扩展的方法,可深入而快速地表征蛋白质-蛋白质界面。未来该技术的广泛应用将生成数据图谱,直接为理性分子胶发现提供信息。
查看英文原文 English abstract
Intracellular protein-protein interactions are key drivers of oncogenic processes such as signal transduction and transcriptional rewiring. While protein-protein interfaces are traditionally hard to drug with small molecules, molecular glues are emerging as a promising modality to redirect the interactions of a target protein away from a pathogenic partner. However, rational discovery of molecular glues remains challenging due to a limited biophysical understanding of how proteins interact at the atomic level. To address this challenge, we developed a massively multiplexed approach to measure the impact of sequence variation on protein-protein interaction affinity inside of eukaryotic cells. Here, we applied this technology to map the binding energetics between CRAF and HRAS at single residue resolution through deep saturation mutagenesis of the CRAF Ras-binding domain (CRAF RBD ). In a single multiplexed assay, we measured binding affinity for 1,501 CRAF variants, including all possible single residue substitutions of the CRAF RBD . Free energy estimates were highly consistent with gold-standard biophysical measurements (Pearson R=0.93, P=6.8×10 -4 , N=8 mutations) and confirmed that our technology could sensitively detect high affinity (nanomolar K D ) and low affinity (micromolar K D ) binding events. Integrating the mutagenesis data with the crystal structure of the interface resulted in a 3D spatial map of binding energetics for the interaction. This map identified orthosteric interface and allosteric non-interface residues that destabilize the interaction. It also revealed a class of sequence variants that simultaneously decrease overall CRAF stability while increasing binding affinity for HRAS. Such mutations may be difficult to discover with traditional biophysical techniques due to the challenge of purifying unstable proteins. Moreover, they can directly inform rational molecular glue design by providing a roadmap for molecules that mimic these strengthening interactions. Finally, we demonstrated that rich mutational energetics data can improve accuracy of AI protein structure prediction models on protein complex prediction tasks. This advancement enables the possibility of generating 3D energetics maps for protein interfaces lacking a solved structure. Our results provide a map of orthosteric and allosteric determinants of CRAF RBD binding to HRAS. This map has direct application to the development of RAS and RAF modulators, a space of high relevance given the emerging landscape of RAS inhibitor resistance mechanisms. This work also demonstrates a highly scalable approach to deeply and rapidly characterize protein-protein interfaces. Future broad application of this technology will generate data atlases to directly inform rational molecular glue discovery.
利益披露 Disclosure
O. Priebe, Serinus Biosciences Employment. C. Khandwala, Serinus Biosciences Employment. F. Guedes, Serinus Biosciences Employment. M. Seaman, Serinus Biosciences Employment. S. Ruppel, Serinus Biosciences Employment. A. Yaari, Serinus Biosciences Employment. M. Sherman, Serinus Biosciences Employment.

← 返回 AACR 2026 检索